These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1822 related articles for article (PubMed ID: 29067492)

  • 1. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
    Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
    Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Zafrir B; Lund LH; Laroche C; Ruschitzka F; Crespo-Leiro MG; Coats AJS; Anker SD; Filippatos G; Seferovic PM; Maggioni AP; De Mora Martin M; Polonski L; Silva-Cardoso J; Amir O;
    Eur Heart J; 2018 Dec; 39(48):4277-4284. PubMed ID: 30325423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure.
    Zhang M; Zhou J
    BMC Cardiovasc Disord; 2024 Sep; 24(1):495. PubMed ID: 39289613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
    Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
    Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction.
    Black-Maier E; Ren X; Steinberg BA; Green CL; Barnett AS; Rosa NS; Al-Khatib SM; Atwater BD; Daubert JP; Frazier-Mills C; Grant AO; Hegland DD; Jackson KP; Jackson LR; Koontz JI; Lewis RK; Sun AY; Thomas KL; Bahnson TD; Piccini JP
    Heart Rhythm; 2018 May; 15(5):651-657. PubMed ID: 29222043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
    Kroshian G; Joseph J; Kinlay S; Peralta AO; Hoffmeister PS; Singh JP; Yuyun MF
    J Cardiovasc Electrophysiol; 2024 Apr; 35(4):715-726. PubMed ID: 38348517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke and Systemic Embolism and Other Adverse Outcomes of Heart Failure With Preserved and Reduced Ejection Fraction in Patients With Atrial Fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]).
    Chung S; Kim TH; Uhm JS; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Kim CS; Lee YS; Shim J; Joung B
    Am J Cardiol; 2020 Jan; 125(1):68-75. PubMed ID: 31699363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry.
    Hao C; Luo J; Liu B; Xu W; Li Z; Gong M; Qin X; Shi B; Wei Y
    Clin Interv Aging; 2022; 17():479-493. PubMed ID: 35444413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
    Slee A; Saad M; Saksena S
    J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.
    Vedin O; Lam CSP; Koh AS; Benson L; Teng THK; Tay WT; Braun OÖ; Savarese G; Dahlström U; Lund LH
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28615366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide.
    Yamauchi R; Morishima I; Okumura K; Kanzaki Y; Morita Y; Takagi K; Nagai H; Watanabe N; Furui K; Yoshioka N; Miyazawa H; Shimojo K; Imaoka T; Sakamoto G; Murohara T
    Europace; 2021 Aug; 23(8):1252-1261. PubMed ID: 33693617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of atrial fibrillation in acute decompensated heart failure with reduced versus preserved ejection fraction.
    Jobs A; Schwind J; Katalinic A; Babaev V; Tilz RR; Rausch S; Thiele H; Eitel I; Eitel C
    Clin Res Cardiol; 2019 Jan; 108(1):74-82. PubMed ID: 29987595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.
    Kato N; Kinugawa K; Shiga T; Hatano M; Takeda N; Imai Y; Watanabe M; Yao A; Hirata Y; Kazuma K; Nagai R
    J Cardiol; 2012 Jul; 60(1):23-30. PubMed ID: 22445598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.